Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human papillomavirus 16/18 vaccine recombinant bivalent - Xiamen Innovax

Drug Profile

Human papillomavirus 16/18 vaccine recombinant bivalent - Xiamen Innovax

Alternative Names: Cecolin; Human papillomavirus (types 16 and 18) L1 virus-like particle vaccine - Xiamen Innovax; Human papillomavirus 16/18 bivalent vaccine recombinant - Xiamen; Human papillomavirus 16/18 vaccine - Xiamen; Recombinant human papillomavirus bivalent (type 16/18) vaccine - Xiamen Innovax

Latest Information Update: 15 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xiamen Innovax Biotech
  • Developer Beijing Wantai Bio-pharm; Xiamen Innovax Biotech; Xiamen University
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Human papillomavirus infections

Highest Development Phases

  • Marketed Cervical cancer; Human papillomavirus infections

Most Recent Events

  • 14 Dec 2023 Xiamen Innovax Biotech completes a phase-III clinical trial in Cervical cancer (Prevention, In adolescents, In children) in Ghana and Bangladesh (IM) (NCT04508309)
  • 10 Jan 2023 Preregistration for Cervical cancer (Prevention, In adolescents, In adults, In children) in Kenya, Cambodia, Malaysia, Indonesia, Kazakhstan, Thailand (IM) before January 2023
  • 10 Jan 2023 Registered for Cervical cancer (Prevention, In adults, In children, In adolescents) in Nepal (IM)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top